WO1989011866A1 - A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria - Google Patents

A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria Download PDF

Info

Publication number
WO1989011866A1
WO1989011866A1 PCT/SE1989/000311 SE8900311W WO8911866A1 WO 1989011866 A1 WO1989011866 A1 WO 1989011866A1 SE 8900311 W SE8900311 W SE 8900311W WO 8911866 A1 WO8911866 A1 WO 8911866A1
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
caries
bactericide
directed against
pharmaceutical preparation
Prior art date
Application number
PCT/SE1989/000311
Other languages
French (fr)
Inventor
Gunnar Fredriksson
Mats Bergryd
Original Assignee
Rama Bio Link Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rama Bio Link Aktiebolag filed Critical Rama Bio Link Aktiebolag
Publication of WO1989011866A1 publication Critical patent/WO1989011866A1/en
Priority to DK289090A priority Critical patent/DK161892C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Definitions

  • a pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria is provided.
  • the invention relates to a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria, and to a pharmaceutical preparation for the treatment of dental plaque and/or caries. Furthermore, it relates to a method of treating dental plaque and/or caries.
  • dental caries and plaque result from the action of certain bacteria in the saliva. Some of these species produce adhesive substances that enable the bacteria to adhere to the tooth surfaces. Bacteria in plaque convert sugars in the diet into acids that dissolve mineral components of the teeth and produce cavities. The plaque-forming bacteria can also colonize crevices between the teeth and gums, moving down along the roots of the teeth, enlarging the crevices and destroying gums, ligaments and bone holding the teeth in the jaw. The disease is a major cause of tooth loss, and the treatment can be both painful and costly. The most important bacterium causative of human dental caries and plaque is Streptococcus mutans, but there are several other bacteria which may participate in the formation of dental plaque and caries and in causing tooth-loosening.
  • the present invention provides a new method of treating dental plaque and caries, in which use is made of a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaqueforming and/or caries-forming bacteria. It has previously been shown that if an antibody is binding to an antigen this will take place in but a few seconds.
  • the conjugate of the invention will attach rapidly to the bacteria against which the antibody of the conjugate is directed, thus keeping the conjugate in place while the bactericide of the conjugate rapidly acts on the target bacteria. Description of the invention
  • the present invention provides a new conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria.
  • the conjugate preferably comprised in a pharmaceutical preparation, is useful in the local treatment of an infection caused by said certain type of dental plaque-forming and/or caries forming bacteria.
  • the invention also provides a method of treating dental plaque and/or caries comprising local application of a bactericidal amount of a conjugate of the invention or a pharmaceutical preparation of the invention, to a surface infected by dental plaque-forming and/or caries-forming bacteria.
  • the bactericide of the conjugate is preferably an antibiotic selected with regard to effectiveness against a certain target bacterium.
  • the antibiotic is Netilmicin (O-3-deoxy-4-C-methyl-3(methyl-amino)- ⁇ -L-arabinopyranosyl-(1 ⁇ 4)-O-[2,6-diamino-2,3,4,6-tetradeoxy- ⁇ -D-gly cero-hex-4-enopyranosyl-(1 ⁇ 6)-2-deoxy-N -ethyl-L-streptamine sulfate (2:5) salt).
  • the antibody of the conjugate is either polyclonal or monoclonal and is directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria.
  • the antibody of the conjugate is preferably directed against at least a certain type of bacteria selected from the group consisting of Streptococcus mutans, Streptococcus sanguis, Bacteroides gingivalis, Actinobacillus actinomycetemcomitans, Eikenella corrodens, Veronella alcalescens and Actinomyces viscosus.
  • the antibody is directed against Streptococcus mutans.
  • the invention further provides a pharmaceutical preparation comprising a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria, together with a pharmaceutically acceptable carrier and/or diluent and, optionally, other pharmaceutically acceptable additives.
  • concentration of the conjugate in the pharmaceutical preparation is preferably such that a single local treatment of an infection caused by a certain type of dental plaque-forming and/or caries-forming bacteria against which the antibody of the conjugate is directed, will provide a bactericidal effect.
  • the pharmaceutically acceptable carrier and diluent which can be used in the pharmaceutical preparation of the invention are not critical, and examples of useful carriers and diluents can be found in the U.S. Pharmacopoeia.
  • the pharmaceutical preparation according to the invention is preferably in the form of a paste, a toothpaste, a suspension, a solution or a mouth-wash.
  • the optional pharmaceutically acceptable additives are such as are needed for the above listed forms of the pharmaceutical preparation.
  • Preferred embodiments of the pharmaceutical preparations of the invention comprise at least one of the preferred conjugates of the invention.
  • a pharmaceutical preparation according to the invention will comprise several conjugates of perhaps different bactericides and different antibodies each directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria.
  • a large number of bacteria were cultivated in conventional LB-medium (the medium was autoclaved before use, and one litre of medium contained 10 g tryptone soya broth (Oxoid code CM 129), 5 g yeast extract (Oxoid code L 21), 10 g NaCl, pH adjusted to 7.5 with 1 M NaOH, and the balance water).
  • the cultivation was performed in an incubator at 37°C and constant agitation overnight.
  • the bacteria for the immunization and affinity purification were washed repeatedly with phosphate buffered saline solution (PBS).
  • PBS phosphate buffered saline solution
  • the bacteria for testing were stored in a refrigerator until use (bacterial medium).
  • Antibodies were produced by repeated immunization of hens (White Leghorn line) with formaline-killed Streptococcus mutans (strain AHT) bacteria.
  • the bacterial strain was received from the Department of Oral Microbiology, Huddinge Hospital, Sweden.
  • the IgG fraction of hyperimmune serum from these animals was received from Immun System AB, Uppsala, Sweden.
  • Purification of antibodues by affinity chromatography Ultrasonicated Streptococcus mutans bacteria of the same strain where coupled to BrCN-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) in a column in conventional manner, and the antibodies were applied onto the column, and then the column was washed with PBS.
  • Bound antibodies were eluted with 0.1 M glycine pH 2.25.
  • the bound specific antibodies were concentrated by precipitation with 50% ammonium sulphate and dialysed against PBS (without azide) for three days.
  • the conjugation of an antibody to a bactericide can be performed in any conventional manner.
  • the method selected was a one-step method using glutaraldehyde.
  • 200 ⁇ l Netilmicin (ESSEX Läkemedel, Box 27190, Sweden) in PBS (5 mg/ml ) was mixed with 50 ⁇ l of 0.2% glutaraldehyde.
  • the mixture was incubated for 1 hour at room temperature.
  • 100 ⁇ l of antibodies in water 0.4 mg antibodies in 0.6 ml H 2 O
  • the mixture was further incubated for two hours at room temperature, whereupon 100 ⁇ l 1 M lysine, pH 7.0, was added.
  • BSA bovine serum albumin
  • Netilmicin was produced as a control. Excess Netilmicin was removed by dialysis against
  • Netilmicin was conjugated to itself, was prepared.
  • the anti-bacterial effect of the conjugates I.
  • the anti-bacterial effect of the conjugates was tested using a conventional technique where the conjugate is placed in wells punched in agar and the size of the inhibition zones is measured. 5 ml of LB agar (LB medium to which 0.7% agar-agar has been added) was poured into a petri dish and allowed to solidify. An additional 5 ml LB agar were heated to
  • the stored bacterial medium in a final dilution of 10 -3 -10 -6 was added to the warm LB agar and rapidly mixed therewith, whereupon the mixture was immediately poured onto the LB agar in the petri dish. Wells were punched in the agar layer, and 20 ⁇ l each of the different samples of conjugate were added to separate wells. The plate was incubated overnight at 37°C, and the next day the diameter of the inhibition zones was measured.
  • the conjugate of antibody-antibiotic has a clearly better anti-bacterial effect on Streptococcus mutans than the same antibiotic conjugated to a non-specific protein.
  • the major advantage of using a conjugate according to the invention for the treatment of dental caries and plaque is the short period of exposure needed for sufficient anti-bacterial effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A conjugated of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria, such as Streptococcus mutans is described. The bactericide of the conjugate is preferably an antibiotic, e.g. Netilmicin. Moreover, pharmaceutical preparations comprising a conjugate of the invention and a method of treating dental plaque and/or caries are described.

Description

A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria.
The invention relates to a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria, and to a pharmaceutical preparation for the treatment of dental plaque and/or caries. Furthermore, it relates to a method of treating dental plaque and/or caries. Background
It is generally accepted that dental caries and plaque result from the action of certain bacteria in the saliva. Some of these species produce adhesive substances that enable the bacteria to adhere to the tooth surfaces. Bacteria in plaque convert sugars in the diet into acids that dissolve mineral components of the teeth and produce cavities. The plaque-forming bacteria can also colonize crevices between the teeth and gums, moving down along the roots of the teeth, enlarging the crevices and destroying gums, ligaments and bone holding the teeth in the jaw. The disease is a major cause of tooth loss, and the treatment can be both painful and costly. The most important bacterium causative of human dental caries and plaque is Streptococcus mutans, but there are several other bacteria which may participate in the formation of dental plaque and caries and in causing tooth-loosening.
The common way of preventing the formation of plaque and caries is tooth-brushing and mechanical cleaning of the teeth by a dentist. Also various agents incorporated into tooth-pastes and mouth-washes help, but they are far from being completely effective. Antibiotics have previously been used for the treatment of caries, but the treatment has required long treatment periods (hours) during which the antibiotic has to be in contact with the infected areas to be effective.
The present invention provides a new method of treating dental plaque and caries, in which use is made of a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaqueforming and/or caries-forming bacteria. It has previously been shown that if an antibody is binding to an antigen this will take place in but a few seconds. The conjugate of the invention will attach rapidly to the bacteria against which the antibody of the conjugate is directed, thus keeping the conjugate in place while the bactericide of the conjugate rapidly acts on the target bacteria. Description of the invention
The present invention provides a new conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria. The conjugate, preferably comprised in a pharmaceutical preparation, is useful in the local treatment of an infection caused by said certain type of dental plaque-forming and/or caries forming bacteria.
Thus, the invention also provides a method of treating dental plaque and/or caries comprising local application of a bactericidal amount of a conjugate of the invention or a pharmaceutical preparation of the invention, to a surface infected by dental plaque-forming and/or caries-forming bacteria.
The bactericide of the conjugate is preferably an antibiotic selected with regard to effectiveness against a certain target bacterium. In a preferred embodiment of the invention, the antibiotic is Netilmicin (O-3-deoxy-4-C-methyl-3(methyl-amino)-β-L-arabinopyranosyl-(1→4)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-gly cero-hex-4-enopyranosyl-(1→6)-2-deoxy-N -ethyl-L-streptamine sulfate (2:5) salt). The antibody of the conjugate is either polyclonal or monoclonal and is directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria.
In said preferred embodiment of the invention, the antibody of the conjugate is preferably directed against at least a certain type of bacteria selected from the group consisting of Streptococcus mutans, Streptococcus sanguis, Bacteroides gingivalis, Actinobacillus actinomycetemcomitans, Eikenella corrodens, Veronella alcalescens and Actinomyces viscosus. In a particularly preferred embodiment of the invention, the antibody is directed against Streptococcus mutans.
The invention further provides a pharmaceutical preparation comprising a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria, together with a pharmaceutically acceptable carrier and/or diluent and, optionally, other pharmaceutically acceptable additives. The concentration of the conjugate in the pharmaceutical preparation is preferably such that a single local treatment of an infection caused by a certain type of dental plaque-forming and/or caries-forming bacteria against which the antibody of the conjugate is directed, will provide a bactericidal effect. The pharmaceutically acceptable carrier and diluent which can be used in the pharmaceutical preparation of the invention are not critical, and examples of useful carriers and diluents can be found in the U.S. Pharmacopoeia.
The pharmaceutical preparation according to the invention is preferably in the form of a paste, a toothpaste, a suspension, a solution or a mouth-wash. The optional pharmaceutically acceptable additives are such as are needed for the above listed forms of the pharmaceutical preparation. Preferred embodiments of the pharmaceutical preparations of the invention comprise at least one of the preferred conjugates of the invention. In practical use it is possible that a pharmaceutical preparation according to the invention will comprise several conjugates of perhaps different bactericides and different antibodies each directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria. Furthermore, it may be necessary to mechanically, e.g. by tooth-brushing, break the polysaccaride capsule of the target bacteria in order to lay bare the immunologically active parts of said bacteria so that the conjugate can attach to and act on the bacteria. As stated above, the most important bacterium causative of dental plaque and caries is Streptococcus mutans, and the invention will therefore be illustrated by a conjugate of an antibiotic and antibodies directed against Streptococcus mutans. Description of the preparation and testing of a preferred conjugate of the invention. Bacterial strain
A large number of bacteria were cultivated in conventional LB-medium (the medium was autoclaved before use, and one litre of medium contained 10 g tryptone soya broth (Oxoid code CM 129), 5 g yeast extract (Oxoid code L 21), 10 g NaCl, pH adjusted to 7.5 with 1 M NaOH, and the balance water). The cultivation was performed in an incubator at 37°C and constant agitation overnight. The bacteria for the immunization and affinity purification were washed repeatedly with phosphate buffered saline solution (PBS). The bacteria for testing were stored in a refrigerator until use (bacterial medium).
Antibodies were produced by repeated immunization of hens (White Leghorn line) with formaline-killed Streptococcus mutans (strain AHT) bacteria. The bacterial strain was received from the Department of Oral Microbiology, Huddinge Hospital, Sweden. The IgG fraction of hyperimmune serum from these animals was received from Immun System AB, Uppsala, Sweden. Purification of antibodues by affinity chromatography Ultrasonicated Streptococcus mutans bacteria of the same strain where coupled to BrCN-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) in a column in conventional manner, and the antibodies were applied onto the column, and then the column was washed with PBS. Bound antibodies were eluted with 0.1 M glycine pH 2.25. The bound specific antibodies were concentrated by precipitation with 50% ammonium sulphate and dialysed against PBS (without azide) for three days. Preparation of conjugate
The conjugation of an antibody to a bactericide can be performed in any conventional manner. The method selected was a one-step method using glutaraldehyde. 200 μl Netilmicin (ESSEX Läkemedel, Box 27190, Stockholm, Sweden) in PBS (5 mg/ml ) was mixed with 50 μl of 0.2% glutaraldehyde. The mixture was incubated for 1 hour at room temperature. To the mixture was added 100 μl of antibodies in water (0.4 mg antibodies in 0.6 ml H2O). The mixture was further incubated for two hours at room temperature, whereupon 100 μl 1 M lysine, pH 7.0, was added. As a control, a non-specific conjugate of bovine serum albumin (BSA), and Netilmicin was produced. Excess Netilmicin was removed by dialysis against
PBS in four stages in two days. The success of the conjugation was verified by using isotope labelled (125I)
Netilmicin. For comparison, also a solution in which
Netilmicin was conjugated to itself, was prepared. The anti-bacterial effect of the conjugates I. The anti-bacterial effect of the conjugates was tested using a conventional technique where the conjugate is placed in wells punched in agar and the size of the inhibition zones is measured. 5 ml of LB agar (LB medium to which 0.7% agar-agar has been added) was poured into a petri dish and allowed to solidify. An additional 5 ml LB agar were heated to
45°C. The stored bacterial medium in a final dilution of 10-3-10-6 was added to the warm LB agar and rapidly mixed therewith, whereupon the mixture was immediately poured onto the LB agar in the petri dish. Wells were punched in the agar layer, and 20 μl each of the different samples of conjugate were added to separate wells. The plate was incubated overnight at 37°C, and the next day the diameter of the inhibition zones was measured.
Results:
Conjugate of Inhibition zone (mm) Antibody-Netilmicin 8
Netilmicin-Netilmicin 7
BSA-Netilmicin 4
II. In order to make conditions as realistic as possible, a system was used where the bacteria grew on a solid surface (simulated tooth), and this surface was subjected to test solutions for a short period of time (simulated mouth-wash) . Nitrocellulose paper strips were incubated for
3-4 hours at room temperature in LB medium containing the bacterial medium diluted 10,000-1,000,000. The paper strips were washed four times with PBS to remove bacteria which had not adhered to the paper. The strips were incubated in A: a specific conjugate (Netilmicin-antibody), B: a non-specific conjugate (Netilmicin-bovine serum albumin), C: Netilmicin conjugated to itself, and D: buffer, for the shortest possible reproducible time, one minute, whereupon they were washed four times with PBS. The incubation solutions A, B and C contained approximately equimolar amounts of Netilmicin. The paper strips were placed on LB agar plates prepared in the same way as above, with the exception that no bacterial agar layer was added. The plates were incubated overnight at 37°C and read the next day. The strips were evaluated as growth or no growth.
Results:
Conjugate of Growth (+) No growth (-)
A. Antibody-Netilmicin - - -
B. BSA-Netilmicin +++
C. Netilmicin-Netilmicin +++ D. Buffer (blank) +++
From the above results, it can be established that the conjugate of antibody-antibiotic has a clearly better anti-bacterial effect on Streptococcus mutans than the same antibiotic conjugated to a non-specific protein. The major advantage of using a conjugate according to the invention for the treatment of dental caries and plaque is the short period of exposure needed for sufficient anti-bacterial effect.

Claims

1. A conjugate of a bactericide and an antibody, c h a r a c t e r i s e d in that the antibody is directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria.
2. A conjugate according to claim 1, c h a r a c t e r i s e d in that the antibody is directed against at least a certain type of bacteria selected from the group consisting of Streptococcus mutans, Streptococcus sanguis, Bacteroides gingivalis, Actinobacillus actinomycetemcomitans, Eikenella corrodens, Veronella alcalescens and Actinomyces viscosus.
3. A conjugate according to claim 1 or 2, c h a r a c t e r i s e d in that the bactericide is an antibiotic.
4. A conjugate according to claim 2 or 3, c h a r a c t e r i s e d in that the bactericide is Netilmicin and the antibody is directed against Streptococcus mutans.
5. A pharmaceutical preparation, c h a r a c t e r i s e d in that it comprises a conjugate of a bactericide and an antibody directed against at least a certain type of dental plaque-forming and/or caries-forming bacteria together with a pharmaceutically acceptable carrier and/or diluent and, optionally, other pharmaceutically acceptable additives.
6. A pharmaceutical preparation according to claim 5, c h a r a c t e r i s e d in that the antibody is directed against at least a certain type of bacteria selected from the group consisting of Streptococcus mutans, Streptococcus sanguis, Bacteroides gingivalis,
Actinobacillus actinomycetemcomitans, Eikenella corrodens, Veronella alcalescens and Actinomyces viscosus.
7. A pharmaceutical preparation according to claim 5 or 6, c h a r a c t e r i s e d in that the bactericide is an antibiotic.
8. A pharmaceutical preparation according to claim
6 or 7, c h a r a c t e r i s e d in that it comprises a conjugate of Netilmicin and an antibody directed against
Streptococcus mutans.
9. A pharmaceutical preparation according to any one of claims 5-8, c h a r a c t e r i s e d in that it is in the form of a paste, a tooth-paste, a suspension, a solution or a mouth-wash.
10. A method of treating dental plaque and/or caries comprising local application of a bactericidal amount of a conjugate according to any one of claims 1-4 or a pharmaceutical preparation according to any one of claims 5-9, to a surface infected by dental plaque-forming and/or caries-forming bacteria.
PCT/SE1989/000311 1988-06-06 1989-06-02 A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria WO1989011866A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK289090A DK161892C (en) 1988-06-06 1990-12-05 PHARMACEUTICAL PREPARATION AND CONJUGATE OF A BACTERICIDE AND ANTIBODY AGAINST PLAQUE-forming OR CARIES-INducing BACTERIES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8802084A SE461570B (en) 1988-06-06 1988-06-06 PHARMACEUTICAL PREPARATION AND CONJUGATED BY A BACTERICID AND ANTIBODY
SE8802084-7 1988-06-06

Publications (1)

Publication Number Publication Date
WO1989011866A1 true WO1989011866A1 (en) 1989-12-14

Family

ID=20372517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1989/000311 WO1989011866A1 (en) 1988-06-06 1989-06-02 A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria

Country Status (5)

Country Link
EP (1) EP0419532A1 (en)
AU (1) AU3763589A (en)
DK (1) DK161892C (en)
SE (1) SE461570B (en)
WO (1) WO1989011866A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450800A1 (en) * 1990-03-21 1991-10-09 Unilever Plc Utilization and delivery of enzymes
EP0453097A2 (en) * 1990-03-21 1991-10-23 Unilever Plc Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
EP0479600A2 (en) * 1990-10-05 1992-04-08 Unilever Plc Delivery of agents
CN101002947B (en) * 2007-01-16 2010-08-25 湖南农业大学 Target medicine used for treating bacteriosis, and its preparing method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952092A (en) * 1972-06-09 1976-04-20 William Henry Bowen Oral preparations
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
WO1987005031A1 (en) * 1986-02-25 1987-08-27 Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952092A (en) * 1972-06-09 1976-04-20 William Henry Bowen Oral preparations
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
WO1987005031A1 (en) * 1986-02-25 1987-08-27 Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450800A1 (en) * 1990-03-21 1991-10-09 Unilever Plc Utilization and delivery of enzymes
EP0453097A2 (en) * 1990-03-21 1991-10-23 Unilever Plc Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
EP0453097A3 (en) * 1990-03-21 1991-10-30 Unilever Plc Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
AU641736B2 (en) * 1990-03-21 1993-09-30 Quest International B.V. Delivery of agents
EP0479600A2 (en) * 1990-10-05 1992-04-08 Unilever Plc Delivery of agents
EP0479600A3 (en) * 1990-10-05 1992-12-09 Unilever Plc Delivery of agents
US5490988A (en) * 1990-10-05 1996-02-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Delivery of therapeutic agents to a target site
CN101002947B (en) * 2007-01-16 2010-08-25 湖南农业大学 Target medicine used for treating bacteriosis, and its preparing method

Also Published As

Publication number Publication date
SE8802084D0 (en) 1988-06-06
SE461570B (en) 1990-03-05
DK289090A (en) 1990-12-05
DK289090D0 (en) 1990-12-05
EP0419532A1 (en) 1991-04-03
DK161892B (en) 1991-08-26
AU3763589A (en) 1990-01-05
SE8802084L (en) 1989-12-07
DK161892C (en) 1992-03-09

Similar Documents

Publication Publication Date Title
Isogai et al. Specific inhibition of adherence of an oral strain of Bacteroides gingivalis 381 to epithelial cells by monoclonal antibodies against the bacterial fimbriae
Herzberg et al. Phenotypic characterization of Streptococcus sanguis virulence factors associated with bacterial endocarditis
Clark et al. Specific inhibition of adsorption of Actinomyces viscosus T14V to saliva-treated hydroxyapatite by antibody against type 1 fimbriae
US4150116A (en) Immunization against dental caries with glucosyltransferase antigens
Röolla et al. Identification of IgA, IgG, lysozyme, albumin, α‐amylase and glucosyltransferase in the protein layer adsorbed to hydroxyapatite from whole saliva
JPS6226236A (en) Conjugate of bacterial protein cell adohessin and polysaccharide
US4250262A (en) Method of preparing a purified glucosyltransferase
Okuda et al. Protective efficacy of active and passive immunizations against experimental infection with Bacteroides gingivalis in ligated hamsters
Bratthall et al. Immunoglobulin A reaction to oral streptococci in saliva of subjects with different combinations of caries and levels of mutans streptococci
IL105119A0 (en) Immunoglobins and antigens for the treatment of staphylococcus infections,methods for the identification and preparation thereof and pharmaceutical compositions containing the same
KR940010861B1 (en) Cell associated glucosyltransferase from streptococcus mutans seroty pe c.e. or f.
DE69738770D1 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
WO1989011866A1 (en) A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria
DE69737323D1 (en) ADHESIN FROM HELIOBACTER PYLORI BINDING TO BLOOD GROUPSANT
JP3098050B2 (en) Delivery of active substance
Umemoto et al. Binding of host‐associated treponeme proteins to collagens and laminin: a possible mechanism of spirochetal adherence to host tissues
US5759544A (en) Antibody-containing oral composition for suppression of periodontal disease
Krasse et al. An anticaries vaccine: report on the status of research
Marandi et al. Characterization of an outer membrane protein of Pasteurella multocida belonging to the OmpA family
CA2038577C (en) Utilization and delivery of enzymes
US5013542A (en) Method to inhibit adhesion of disease-causing microorganisms to teeth
WAALER Further in vivo studies on the plaque‐inhibiting effect of chlorhexidine and its binding mechanisms
JPS60146834A (en) Production of antibody for inhibiting periodontitis and noncarious composition containing said antibody
Kurono et al. Inhibition of nasopharyngeal colonization of Hemophilus influenzae by oral immunization
Hamada et al. Characterization of a monoclonal antibody specific for lipoteichoic acid from various Gram‐positive bacteria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989906837

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989906837

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989906837

Country of ref document: EP